PLN 4.28
(7.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 15.34 Million PLN | -1.55% |
2022 | 15.4 Million PLN | 10.16% |
2021 | 13.09 Million PLN | 117.64% |
2020 | 10.84 Million PLN | -44.22% |
2019 | 11.65 Million PLN | 7669.33% |
2018 | -29.48 Million PLN | 107.38% |
2017 | 11.9 Million PLN | -21.45% |
2016 | -17.87 Million PLN | 94.52% |
2015 | -30.52 Million PLN | -725.54% |
2014 | 4.47 Million PLN | -34.05% |
2013 | 5.45 Million PLN | 14026.54% |
2012 | -1.48 Million PLN | -100.77% |
2011 | 6.83 Million PLN | 548.42% |
2010 | 7.57 Million PLN | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 2.59 Million PLN | -62.96% |
2024 Q2 | 4.31 Million PLN | 62.72% |
2023 Q4 | 6.96 Million PLN | 704.77% |
2023 Q3 | -1.15 Million PLN | -119.74% |
2023 Q2 | 5.83 Million PLN | 81.02% |
2023 FY | - PLN | -1.55% |
2023 Q1 | 3.22 Million PLN | -39.24% |
2022 Q4 | 5.3 Million PLN | 30.02% |
2022 Q3 | 4.08 Million PLN | -26.94% |
2022 Q2 | 5.58 Million PLN | 365.11% |
2022 Q1 | 1.2 Million PLN | -79.67% |
2022 FY | - PLN | 10.16% |
2021 Q1 | 657 Thousand PLN | -78.45% |
2021 Q2 | 5.75 Million PLN | 775.95% |
2021 Q3 | 1.39 Million PLN | -75.69% |
2021 FY | - PLN | 117.64% |
2021 Q4 | 5.9 Million PLN | 322.3% |
2020 Q4 | 3.04 Million PLN | 46.02% |
2020 FY | - PLN | -44.22% |
2020 Q1 | 3.79 Million PLN | 1.15% |
2020 Q2 | 1.47 Million PLN | -61.19% |
2020 Q3 | 2.08 Million PLN | 41.94% |
2019 FY | - PLN | 7669.33% |
2019 Q1 | 2.43 Million PLN | 106.84% |
2019 Q2 | 2.45 Million PLN | 0.7% |
2019 Q3 | 2.93 Million PLN | 19.74% |
2019 Q4 | 3.74 Million PLN | 27.62% |
2018 Q4 | -35.59 Million PLN | -2620.54% |
2018 Q3 | 1.41 Million PLN | -6.24% |
2018 Q2 | 1.5 Million PLN | -16.01% |
2018 Q1 | 1.79 Million PLN | -90.48% |
2018 FY | - PLN | 107.38% |
2017 Q3 | 2.78 Million PLN | 123.26% |
2017 FY | - PLN | -21.45% |
2017 Q4 | 18.84 Million PLN | 575.86% |
2017 Q2 | -11.98 Million PLN | -1026.2% |
2017 Q1 | 1.29 Million PLN | 1587.36% |
2016 Q3 | -454 Thousand PLN | 89.98% |
2016 Q4 | -87 Thousand PLN | 80.84% |
2016 FY | - PLN | 94.52% |
2016 Q1 | 2.41 Million PLN | 108.22% |
2016 Q2 | -4.53 Million PLN | -288.01% |
2015 Q2 | 958 Thousand PLN | 205.16% |
2015 Q3 | -1.26 Million PLN | -231.94% |
2015 FY | - PLN | -725.54% |
2015 Q4 | -29.3 Million PLN | -2218.57% |
2015 Q1 | -911 Thousand PLN | -135.66% |
2014 Q3 | -150.91 Thousand PLN | -109.14% |
2014 FY | - PLN | -34.05% |
2014 Q1 | 735.71 Thousand PLN | -67.79% |
2014 Q2 | 1.65 Million PLN | 124.3% |
2014 Q4 | 2.55 Million PLN | 1792.9% |
2013 Q4 | 2.28 Million PLN | -2.39% |
2013 Q2 | 973.42 Thousand PLN | -45.96% |
2013 Q3 | 2.34 Million PLN | 140.4% |
2013 Q1 | 1.8 Million PLN | 173.62% |
2013 FY | - PLN | 14026.54% |
2012 Q4 | -2.44 Million PLN | -5108.99% |
2012 FY | - PLN | -100.77% |
2012 Q2 | 961.36 Thousand PLN | -30.51% |
2012 Q3 | 48.84 Thousand PLN | -94.92% |
2012 Q1 | 1.38 Million PLN | 0.0% |
2011 FY | - PLN | 548.42% |
2010 FY | - PLN | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Bioceltix S.A. | -13.22 Million PLN | 216.043% |
BIOTON S.A. | 43.89 Million PLN | 65.041% |
Captor Therapeutics Spolka Akcyjna | -64.76 Million PLN | 123.695% |
Mabion S.A. | 58.31 Million PLN | 73.683% |
Molecure S.A. | -25.5 Million PLN | 160.167% |
NanoGroup S.A. | -7.87 Million PLN | 294.987% |
Pharmena S.A. | 33.78 Million PLN | 54.571% |
Poltreg S.A. | -11.65 Million PLN | 231.624% |
Pure Biologics Spólka Akcyjna | -26.07 Million PLN | 158.849% |
Ryvu Therapeutics S.A. | -81.04 Million PLN | 118.935% |
Urteste S.A. | -5.73 Million PLN | 367.772% |